Amyloidosis
IRB #H-31546: A Pilot Study of Doxycycline For Amyloidosis (This single-center, twelve-month, open-label, prospective, pilot phase II study aims to determine whether doxycycline reduces amyloid deposits and improves organ function in patients with systemic or localized amyloidosis.)
IRB #H-28441/X05292: Phase II Trial of Induction Therapy with Bortezomib and Dexamethasone followed by High-Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis
IRB #2006-1918/Merck V212: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
IRB #H-31082/Pomalidomide: A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects with Previously-Treated AL Amyloidosis
WIRB #pend/AMyC 11-MM-02: A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis (not yet submitted to the IRB)
IRB #31928/CUMC: Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
IRB #2012-1122/Millennium C16011: A Phase III, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
IRB #pend/Neotope NEOD001-001: A Phase I, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects with Light Chain (AL) Amyloidosis (Not yet submitted to the IRB)
IRB #pend/Karmanos #2011-155: Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease (Not yet submitted to the IRB)
